当前位置: X-MOL 学术Clin. Exp. Allergy › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?
Clinical & Experimental Allergy ( IF 6.1 ) Pub Date : 2020-07-14 , DOI: 10.1111/cea.13694
John W Upham 1, 2 , Lisa M Jurak 1
Affiliation  

While there has been much interest in using biomarkers to select patients for particular targeted therapies, there has been much less attention paid to how these biomarkers change in patients once treatment begins. This is an area of great interest to practising clinicians, especially respiratory physicians and allergists who manage severe asthma. In this article, we review monoclonal antibodies and related targeted therapies, especially those that are currently available or in late stage clinical trials, focussing on the differential effects such agents have on biomarkers in widespread clinical practice such as eosinophils, FeNO and total IgE. Serial measurements of biomarkers can be useful in determining whether a particular targeted therapy is having its expected biological effect and invaluable in assessing the reasons for treatment failure should that occur.

中文翻译:

生物制品和其他新疗法如何影响临床使用的严重哮喘生物标志物?

尽管人们对使用生物标志物为特定靶向治疗选择患者很感兴趣,但很少有人关注治疗开始后这些生物标志物如何在患者体内发生变化。这是临床医生非常感兴趣的领域,尤其是呼吸系统医生和治疗严重哮喘的过敏症专家。在本文中,我们回顾了单克隆抗体和相关靶向治疗,尤其是那些目前可用或处于后期临床试验中的单克隆抗体,重点关注这些药物对广泛临床实践中的生物标志物(如嗜酸性粒细胞、FeNO 和总 IgE)的不同影响。
更新日期:2020-07-14
down
wechat
bug